These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29757489)

  • 1. Emergency Department Discharge of Pulmonary Embolus Patients.
    Frank Peacock W; Coleman CI; Diercks DB; Francis S; Kabrhel C; Keay C; Kline JA; Manteuffel J; Wildgoose P; Xiang J; Singer AJ
    Acad Emerg Med; 2018 Sep; 25(9):995-1003. PubMed ID: 29757489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design.
    Singer AJ; Xiang J; Kabrhel C; Merli GJ; Pollack C; Tapson VF; Wildgoose P; Peacock WF
    Acad Emerg Med; 2016 Nov; 23(11):1280-1286. PubMed ID: 27537530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism.
    Weeda ER; Kohn CG; Peacock WF; Fermann GJ; Crivera C; Schein JR; Coleman CI
    Pharmacotherapy; 2016 Oct; 36(10):1109-1115. PubMed ID: 27548074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immediate Discharge and Home Treatment With Rivaroxaban of Low-risk Venous Thromboembolism Diagnosed in Two U.S. Emergency Departments: A One-year Preplanned Analysis.
    Beam DM; Kahler ZP; Kline JA
    Acad Emerg Med; 2015 Jul; 22(7):788-95. PubMed ID: 26113241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin.
    Weeda ER; Wells PS; Peacock WF; Fermann GJ; Baugh CW; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
    Intern Emerg Med; 2017 Apr; 12(3):311-318. PubMed ID: 27757790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism.
    Wang L; Baser O; Wells P; Peacock WF; Coleman CI; Fermann GJ; Schein J; Crivera C
    Clin Ther; 2017 Jul; 39(7):1426-1436.e2. PubMed ID: 28652016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial.
    Barco S; Lankeit M; Binder H; Schellong S; Christ M; Beyer-Westendorf J; Duerschmied D; Bauersachs R; Empen K; Held M; Schwaiblmair M; Fonseca C; Jiménez D; Becattini C; Quitzau K; Konstantinides S
    Thromb Haemost; 2016 Jul; 116(1):191-7. PubMed ID: 27010343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
    Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
    Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.
    Barco S; Schmidtmann I; Ageno W; Bauersachs RM; Becattini C; Bernardi E; Beyer-Westendorf J; Bonacchini L; Brachmann J; Christ M; Czihal M; Duerschmied D; Empen K; Espinola-Klein C; Ficker JH; Fonseca C; Genth-Zotz S; Jiménez D; Harjola VP; Held M; Iogna Prat L; Lange TJ; Manolis A; Meyer A; Mustonen P; Rauch-Kroehnert U; Ruiz-Artacho P; Schellong S; Schwaiblmair M; Stahrenberg R; Westerweel PE; Wild PS; Konstantinides SV; Lankeit M;
    Eur Heart J; 2020 Jan; 41(4):509-518. PubMed ID: 31120118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK; Haskell L; Bamber L; Wang M; Schein J; Mody SH
    J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost of Treating Venous Thromboembolism With Heparin and Warfarin Versus Home Treatment With Rivaroxaban.
    Kahler ZP; Beam DM; Kline JA
    Acad Emerg Med; 2015 Jul; 22(7):796-802. PubMed ID: 26111453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions.
    Margolis JM; Deitelzweig S; Kline J; Tran O; Smith DM; Bookhart B; Crivera C; Schein J
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy: an academic centre experience.
    Paczyńska M; Kurnicka K; Lichodziejewska B; Goliszek S; Dzikowska-Diduch O; Sobieraj P; Burzyński Ł; Kostrubiec M; Pruszczyk P; Ciurzyński M
    Kardiol Pol; 2016; 74(7):650-6. PubMed ID: 26779849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?
    Coleman CI; Fermann GJ; Weeda ER; Wells PS; Ashton V; Crivera C; Bunz TJ; Wildgoose P; Schein JR; Peacock WF
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):830-837. PubMed ID: 27481875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
    Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
    Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care.
    Peacock WF; Coleman CI; Wells P; Fermann GJ; Wang L; Baser O; Schein J; Crivera C
    J Health Econ Outcomes Res; 2019; 6(3):160-173. PubMed ID: 32685588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With Warfarin.
    Margolis JM; Deitelzweig S; Kline J; Tran O; Smith DM; Crivera C; Bookhart B; Schein J
    Clin Ther; 2016 Nov; 38(11):2496-2503. PubMed ID: 27751675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Implementation of a Novel Management Protocol Increases the Outpatient Treatment of Pulmonary Embolism and Deep Vein Thrombosis.
    Kabrhel C; Rosovsky R; Baugh C; Connors J; White B; Giordano N; Torrey J; Deadmon E; Parry BA; Hagan S; Zheng H
    Acad Emerg Med; 2019 Jun; 26(6):657-669. PubMed ID: 30341928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.